Connor Clark & Lunn Investment Management Ltd. Purchases New Shares in Edwards Lifesciences Corporation $EW

Connor Clark & Lunn Investment Management Ltd. acquired a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 48,589 shares of the medical research company’s stock, valued at approximately $3,800,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $266,000. CWM LLC raised its stake in shares of Edwards Lifesciences by 36.3% in the first quarter. CWM LLC now owns 32,916 shares of the medical research company’s stock worth $2,386,000 after acquiring an additional 8,772 shares during the last quarter. Signaturefd LLC lifted its position in shares of Edwards Lifesciences by 11.5% during the first quarter. Signaturefd LLC now owns 6,202 shares of the medical research company’s stock worth $450,000 after purchasing an additional 638 shares in the last quarter. Sigma Planning Corp grew its stake in shares of Edwards Lifesciences by 4.9% during the first quarter. Sigma Planning Corp now owns 4,055 shares of the medical research company’s stock valued at $294,000 after purchasing an additional 191 shares during the last quarter. Finally, Apollon Wealth Management LLC grew its stake in shares of Edwards Lifesciences by 8.9% during the first quarter. Apollon Wealth Management LLC now owns 7,916 shares of the medical research company’s stock valued at $574,000 after purchasing an additional 645 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $86.35 on Friday. The firm has a market capitalization of $50.11 billion, a P/E ratio of 12.42, a PEG ratio of 3.97 and a beta of 1.03. The business has a 50-day moving average of $78.20 and a 200-day moving average of $77.72. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1 year low of $65.31 and a 1 year high of $87.21.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter last year, the firm earned $0.67 EPS. Edwards Lifesciences’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

EW has been the topic of several research reports. Daiwa America raised Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Robert W. Baird set a $83.00 target price on Edwards Lifesciences in a research report on Friday, October 31st. National Bankshares set a $92.00 price objective on Edwards Lifesciences in a research report on Friday, October 31st. JPMorgan Chase & Co. boosted their price objective on Edwards Lifesciences from $85.00 to $90.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Finally, Wells Fargo & Company raised their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a research note on Thursday, August 7th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $91.39.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at $3,314,725.84. This represents a 24.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 22,970 shares of company stock worth $1,862,878 in the last quarter. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.